Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.
Dr. Geoffrey Liu
Advertisement
Articles by Dr. Geoffrey Liu
Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
New Strategy May Prevent Breast Cancer Relapse
2
Why Multidisciplinary Care is Crucial in Prostate Cancer
3
FDA Approves Enoby and Xtrenbo Biosimilars for Bone Health and Cancer Care
4
Understanding the Evolving Role of a Pathologist in Lung Cancer Care
5
